Last updated July 18, 2026
Key finding
Mean change in % (mmol/mol) HbA1c was significantly more with GLIME+VOGLI+MET-ER versus VOGLI+MET and GLIME+MET at Week 12 (-1.02 ± 0.60 vs. -0.68 ± 0.64, p < 0.001).
This study evaluated the efficacy and safety of a fixed-dose combination of glimepiride, voglibose, and extended-release metformin in adults with Type 2 Diabetes Mellitus, showing significant reductions in HbA1c levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of a fixed-dose combination of glimepiride, voglibose, and extended-release metformin in adults with Type 2 Diabetes Mellitus, showing significant reductions in HbA1c levels.
This research is significant as it provides evidence for a more effective treatment option for adults with Type 2 Diabetes Mellitus, potentially leading to better management of blood sugar levels. The findings could help clinicians make informed decisions about prescribing diabetes medications, ultimately improving patient outcomes.
The study did not specify changes in fasting and postprandial blood glucose levels. The proportion of participants achieving HbA1c < 7.0% was not reported. Limited details on the nature and severity of adverse events.
Published in
Publication details and source links for this paper.
Brij M, S. VK, Prakash HK, et al. Efficacy and Safety of a Fixed-Dose Combination of Glimepiride, Voglibose, and Metformin in Adults with Type 2 Diabetes Mellitus: A Phase IV Randomized Controlled Trial. Journal of Diabetes. 2026;18(4):e70217. doi:10.1111/1753-0407.70217
GLIME+VOGLI+MET-ER reduced HbA1c by -1.02% at Week 12 compared to VOGLI+MET (-0.68%) and GLIME+MET (-0.88%), p < 0.001.
At Week 24, GLIME+VOGLI+MET-ER showed a mean HbA1c reduction of -1.57% versus -1.11% for VOGLI+MET and -1.28% for GLIME+MET, p < 0.001.
A total of 49 adverse events were reported in 32 out of 399 patients (8.0%).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Metformin + glimepiride and Fasting blood sugar (FBS), HbA1c, Postprandial blood glucose, and 2 more.
This study contributes evidence to
Primary intervention
Metformin + glimepiride
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
5
Evidence pairs
579
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Metformin + glimepiride → Fasting blood sugar (FBS)
Metformin + glimepiride → Fasting blood sugar (FBS)
Metformin + glimepiride → Postprandial blood glucose
Metformin + glimepiride → Postprandial blood glucose
Metformin + glimepiride → Proportion achieving HbA1c <7.0%
Metformin + glimepiride → Proportion achieving HbA1c <7.0%
Metformin + glimepiride → Treatment-emergent adverse events
Metformin + glimepiride → Treatment-emergent adverse events
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and HbA1c, Metformin Therapies and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Metformin Therapies
Contributes to Metformin Therapies evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Metformin Therapies may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
Metformin Therapies appears to improve HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Proportion achieving HbA1c <7.0%
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 13 supporting studies with generally consistent results and a positive effect signal.
Limitations
Metformin Therapies may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Postprandial blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of Metformin + glimepiride for Treatment-emergent adverse events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Treatment-emergent adverse events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
